Primary Cutaneous Langerhans Cell Histiocytosis Treated with Photochemotherapy

Kwon, Oh Sang; Cho, Kwang Hyun; Song, Kye Yong

doi:10.1111/j.1346-8138.1997.tb02740.x

Cited by 20 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In suspected cases, biopsy is imperative in order not to overlook systemic involvement. Treatment options are surgical excision in isolated lesions, as well as topical steroids, topical nitrogen mustard, psoralen+UVA (PUVA), tacrolimus, and thalidomide and interferon combination (9)(10)(11). In our patient, the isolated lesion localized in the scalp regressed with topical steroid treatment.…”

Section: Discussionmentioning

confidence: 82%

A case of Langerhans Cell Histiocytosis with Multisystemic Involvement in an Adult Patient

Demirel¹,

Tekin²,

Barut³

et al. 2016

Erciyes Med J

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) is a rare group of idiopathic diseases characterized by abnormal proliferation of bone marrow-derived dendritic cells called histiocytes. It is more common in childhood, but in the literature, some adult cases have been reported. For several reasons, the disease is more familiar to pediatricians than it is to physicians handling adult cases; therefore, the diagnosis of adult cases is often delayed or missed. The clinical course of LCH is variable, ranging from a self-healing solitary bone lesion to a widely disseminated life-threatening disease. The diagnosis of LCH should be based on histologic and immunophenotypic examination of perilesional skin. In this report, we present a case of LCH in a 66-yearold woman with bone, skin, and pituitary gland involvement; this case emphasizes that a patient with LCH should undergo careful multidisciplinary evaluation.

show abstract

Section: Discussionmentioning

confidence: 82%

A case of Langerhans Cell Histiocytosis with Multisystemic Involvement in an Adult Patient

Demirel¹,

Tekin²,

Barut³

et al. 2016

Erciyes Med J

View full text Add to dashboard Cite

show abstract

“…An adult with multiresistant cutaneous LCH was successfully treated with methotrexate (20 mg/IV/week) . Psoralen plus ultraviolet A (PUVA) therapy is considered effective in extensive cutaneous disease that is resistant to oral therapies . However, PUVA should only be given in older children for short periods of time due to the risk of secondary malignancies.…”

Section: Discussionmentioning

confidence: 99%

“…[24] Psoralen plus ultraviolet A (PUVA) therapy is considered effective in extensive cutaneous disease that is resistant to oral therapies. [25] However, PUVA should only be given in older children for short periods of time due to the risk of secondary malignancies. Narrow band ultraviolet B therapy is an alternative that has been tried in a few children with good results for skin lesions.…”

Section: Discussionmentioning

confidence: 99%

Diverse Cutaneous Presentations of Langerhans Cell Histiocytosis in Children: A Retrospective Cohort Study

Morren

Broecke

Vangeebergen

et al. 2015

Pediatr Blood Cancer

View full text Add to dashboard Cite

show abstract

“…16 Oral 8-methoxypsoralen (8-MOP) plus ultraviolet A (PUVA) therapy (3 times per week for two months, 1–2 times per week maintenance PUVA) is an interesting treatment option, in particular offering treatment to patients presenting extensive cutaneous disease. 17–19 Low-dose methotrexate (20 mg weekly) successfully treated multiresistant cutaneous LCH. 20,21 In some patients with multiresistant cutaneous LCH, subcutaneous interferon- α2b achieved long remission periods.…”

Section: Discussionmentioning

confidence: 99%

Photodynamic therapy for multi-resistant cutaneous Langerhans cell histiocytosis

et al. 2010

View full text Add to dashboard Cite

Langerhans cell histiocytosis is a rare group of proliferative disorders. Beside cutaneous involvement, other internal organs can be affected. The treatment of cutaneous lesions is difficult and relies on topical corticosteroids, carmustine, nitrogen mustard, and photochemotherapy. Systemic steroids and vinblastine are used for recalcitrant skin lesions. However, some cases fail to respond. An 18-month old boy presented a CD1a+, S100a+ Langerhans cell histocytosis with cutaneous and severe scalp involvement. Topical corticosteroids and nitrogen mustard failed to improve the skin lesions. Systemic corticosteroids and vinblastine improved the truncal involvement but had no effect on the scalp lesions. Methylaminolevulinate (MAL) based photodynamic therapy (PDT) resulted in a significant regression of the scalp lesions. Control histology revealed an almost complete clearance of the tumor infiltrate. Clinical follow-up after six months showed no recurrence.Although spontaneous regression of cutaneous Langerhans cell histiocytosis is observed, the rapid effect of photodynamic therapy after several failures of other treatment suggests that photodynamic therapy was successful. As far as we know this is the first report of photodynamic therapy for refractory skin lesions. Larger series are needed to determine whether photodynamic therapy deserves a place in the treatment of multiresistant cutaneous Langerhans cell histiocytosis.

show abstract

Primary Cutaneous Langerhans Cell Histiocytosis Treated with Photochemotherapy

Cited by 20 publications

References 6 publications

A case of Langerhans Cell Histiocytosis with Multisystemic Involvement in an Adult Patient

A case of Langerhans Cell Histiocytosis with Multisystemic Involvement in an Adult Patient

Diverse Cutaneous Presentations of Langerhans Cell Histiocytosis in Children: A Retrospective Cohort Study

Photodynamic therapy for multi-resistant cutaneous Langerhans cell histiocytosis

Contact Info

Product

Resources

About